Key result
Atrial fibrillation significantly increased the risk of all-cause mortality (OR 2.75) compared to patients without atrial fibrillation in patients with hypertrophic cardiomyopathy.
Why the study?
The study was conducted to systematically evaluate the prognostic impact of atrial fibrillation on survival and cardiovascular events in patients with hypertrophic cardiomyopathy.
Does atrial fibrillation increase the risk of mortality in patients with hypertrophic cardiomyopathy?
Meta-Analysis (n=27,369)
Does atrial fibrillation increase the risk of mortality in patients with hypertrophic cardiomyopathy?
Effect estimate: OR 2.75 (95% CI 2.18-3.47)
p-value: p=<0.001
Atrial fibrillation is a significant risk factor for all-cause and cardiovascular mortality in patients with hypertrophic cardiomyopathy.
AF warrants consideration in HCM risk stratification; confirms mortality link in pooled data but leaves causal effects open.
Objective To systematically evaluate the prognostic impact of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM). Methods The Chinese and English databases (PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, and Wanfang database were systematically searched to include observational studies on the prognosis of AF in cardiovascular events or death in patients with HCM; these were evaluated using Revman 5.3. Results After systematic search and screening, a total of 11 studies with a high study quality were included in this study. Meta-analysis showed that patients with HCM accompanied by AF had a higher risk of all-cause death (odds ratio [OR] = 2.75; 95% confidence interval [CI]: 2.18–3.47; P < 0.001), heart-related death (OR = 2.62; 95%CI: 2.02–3.40; P < 0.001), sudden cardiac death (OR = 7.09; 95%CI: 5.77–8.70; P < 0.001), heart-failure-related death (OR = 2.04; 95%CI: 1.24–3.36; P = 0.005), and stroke death (OR = 17.05; 95%CI: 6.99–41.58; P < 0.001) compared with patients with HCM without AF. Conclusion Atrial fibrillation is a risk factor for adverse survival outcomes in patients with HCM, and aggressive interventions are needed in this population to avoid the occurrence of adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Du et al. (2023) conducted a meta-analysis in Hypertrophic cardiomyopathy (n=27,369). Atrial fibrillation vs. Without atrial fibrillation was evaluated on All-cause mortality (OR 2.75, 95% CI 2.18-3.47, p=<0.001). Atrial fibrillation significantly increased the risk of all-cause mortality (OR 2.75) compared to patients without atrial fibrillation in patients with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: